Circ-ZEB1.33 promotes the proliferation of human HCC by sponging miR-200a-3p and upregulating CDK6

about

Circ-ZEB1.33 promotes the proliferation of human HCC by sponging miR-200a-3p and upregulating CDK6

Item

http://www.wikidata.org/entity/Q58786576

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Circ-ZEB1.33 promotes the prol ...... -200a-3p and upregulating CDK6

@en

Circ-ZEB1.33 promotes the prol ...... -200a-3p and upregulating CDK6

@nl

type

Item

label

Circ-ZEB1.33 promotes the prol ...... -200a-3p and upregulating CDK6

@en

Circ-ZEB1.33 promotes the prol ...... -200a-3p and upregulating CDK6

@nl

prefLabel

Circ-ZEB1.33 promotes the prol ...... -200a-3p and upregulating CDK6

@en

Circ-ZEB1.33 promotes the prol ...... -200a-3p and upregulating CDK6

@nl

P1476

Circ-ZEB1.33 promotes the prol ...... -200a-3p and upregulating CDK6

@en

P2093

Di Wu

http://www.w3.org/2001/XMLSchema#string

Jinzhong Mao

http://www.w3.org/2001/XMLSchema#string

Liang Zhu

http://www.w3.org/2001/XMLSchema#string

Long Li

http://www.w3.org/2001/XMLSchema#string

Rong Song

http://www.w3.org/2001/XMLSchema#string

Xuemei Wang

http://www.w3.org/2001/XMLSchema#string

Yuhua Gong

http://www.w3.org/2001/XMLSchema#string

P2860

Epigenetic regulation of the INK4b-ARF-INK4a locus: in sickness and in health

Targeting CDK4 and CDK6: From Discovery to Therapy

CircNet: a database of circular RNAs derived from transcriptome sequencing data

Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase.

Phosphodiesterase 3/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition.

Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality.

Treating cancer with selective CDK4/6 inhibitors.

Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future.

Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?

Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.

P2888

s12935-018-0602-3

P304

116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12935-018-0602-3

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1106141252

http://www.w3.org/2001/XMLSchema#string

P698

30123094

http://www.w3.org/2001/XMLSchema#string

P921

cancer research

P932

6090603

http://www.w3.org/2001/XMLSchema#string